Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 62, Issue 5, 2015, Pages 743-750

  Burke, Michael J ^a   Ahern, Charlotte ^b   Weigel, Brenda J ^c   Poirier, John T ^d   Rudin, Charles M ^d   Chen, Yingbei ^d   Cripe, Timothy P ^e   Bernhardt, M Brooke ^f   Blaney, Susan M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Oncolytic; Pediatric; Relapsed; Seneca valley virus; Solid tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; NTX 010; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; ALKYLATING AGENT; NEUTRALIZING ANTIBODY;

ABDOMINAL PAIN; ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER PAIN; CARCINOID; CHILD; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; EMBRYONAL RHABDOMYOSARCOMA; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPONATREMIA; LEUKOCYTE; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSED REFRACTORY SOLID TUMOR; RHABDOMYOSARCOMA; RNA VIRUS; SENECA VALLEY VIRUS; SOLID TUMOR; THROMBOCYTE COUNT; VIRUS PARTICLE; VOMITING; BLOOD; CANCER STAGING; CLINICAL TRIAL; DRUG RESISTANCE; FOLLOW UP; MULTIMODALITY CANCER THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PICORNAVIRIDAE; PRESCHOOL CHILD; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PICORNAVIRIDAE; PROGNOSIS; SALVAGE THERAPY; YOUNG ADULT;

EID: 84925352074     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25269     Document Type: Article

References (26)

1. nd Edition New York: Raven Press; 1990.
2. Reddy PS, Burroughs KD, Hales LM, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007; 99:1623-1633.
3. Morton CL, Houghton PJ, Kolb EA, et al. Initial testing of the replication competent Seneca valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55:295-303.
4. Yu L, Baxter PA, Zhao X, et al. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol 2011; 13:14-27.
5. Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res 2011; 17:888-895.
6. Yang L, Pang Y, Moses HL, TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220-227.
7. Melcher A, Parato K, Rooney CM, et al. Thunder and lightning: Immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19:1008-1016.
8. Kelly E, Russell SJ. History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 2007; 15:651-659.
9. Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19:1737-1746.
10. Waggott D, Chu K, Yin S, et al. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics 2012; 28:1546-1548.
11. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 2012; 40:e133.
12. Trzonkowski P, Szarynska M, Mysliwska J, et al. Ex vivo expansion of CD4 (+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A 2009; 75:175-188.
13. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-670.
14. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 2001; 1:525-538.
15. Laurie SA, Bell JC, Atkins HL, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 2006; 12:2555-2562.
16. Freytag SO, Movsas B, Aref I, et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007; 15:1016-1023.
17. Lorence RM, Roberts MS, O'Neil JD, et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 2007; 7:157-167.
18. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 2008; 9:533-542.
19. Aghi MK, Chiocca EA. Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 2009; 17:8-9.
20. Li JL, Liu HL, Zhang XR, et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther 2009; 16:376-382.
21. Pesonen S, Nokisalmi P, Escutenaire S, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010; 17:892-904.
22. Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011; 19:1913-1922.
23. Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012; 12:99. doi: 10.1186/1471-2407-12-99.
24. Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937-1947.
25. Sampath P, Li J, Hou W, et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 2013; 21:620-628.
26. Workenhe ST, Simmons G, Pol JG, et al. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014; 22:123-131.